ESAB Corporation (ESAB) Cash Flow Statement

The wide oscillation in OCF/NI, from 0.53 to 2.58, suggests that reported earnings are not consistently backed by cash generation, with working capital changes driving the divergence. The 2026Q2 ratio of 1.03 aligns with net income, but the prior quarters' extremes imply that quarterly earnings quality is heavily influenced by timing of collections and payables. Investors should monitor whether the recent stabilization reflects improved operational efficiency or merely a lull in working capital swings.

The FCF margin's sharp decline in 2026Q2, despite revenue growth, indicates that operating cash flow has not kept pace with top-line expansion, possibly due to working capital outflows. The average FCF margin over the last four quarters is approximately 6.5%, below the 2024 average of 11.1%, suggesting a structural step-down in cash conversion efficiency. This trend warrants close attention as management's raised guidance implies improved profitability, but cash generation has yet to confirm that optimism.

The consistent low capex-to-revenue ratio, averaging around 1.8% excluding the 2024Q4 outlier, suggests that ESAB's asset base is not heavily capital-intensive, which is typical for a consumables-driven model. This implies that most of the operating cash flow is available for debt reduction, dividends, or acquisitions, supporting the company's ability to deleverage post-spin-off. However, the slight uptick in 2026Q2 to 2.2% may indicate incremental investment in automation or capacity, which could be a positive sign for future growth.

The large swings in working capital, particularly the $91.4M positive contribution in 2025Q3 and the -$49.5M drag in 2025Q1, indicate that ESAB's cash flow is highly sensitive to inventory and receivables management. The negative working capital changes in 2026Q1 and Q2, totaling -$57.1M, suggest a build-up in inventory or receivables that has not yet converted to cash, which may be a leading indicator of slowing demand or channel stocking issues. Investors should monitor whether these outflows reverse in subsequent quarters, as persistent negative changes could signal deteriorating cash conversion.

The $1.5B acquisition outflow in 2026Q2, likely for the Ohio Medical or similar deal, represents a significant capital allocation decision that may strain near-term liquidity despite the modest dividend. The absence of share repurchases suggests management is prioritizing growth investments over returning capital to shareholders, which is consistent with a post-spin-off strategy to build scale. The dividend payout, while small, appears sustainable given operating cash flow, but the acquisition's integration risk and its impact on future cash generation warrant close monitoring.

The cumulative OCF of $696.3M versus net income of $571.6M indicates that, on a cumulative basis, cash generation has been stronger than earnings, which is a positive sign. However, the 2026Q2 acquisition outflow of $1.5B distorts the picture, and excluding that, the cumulative OCF would be even higher relative to net income. This suggests that the company's earnings quality is generally sound, but the recent acquisition may pressure future cash flows if integration costs or working capital needs rise.